Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
1997-1-30
|
pubmed:abstractText |
The question whether the immunomodulating activity of rac-thalidomide resides in either the (-)-(S)- or the (+)-(R)-enantiomer was addressed by synthesis and separation of pure enantiomers of thalidomide analogues which carry a methyl-group at the asymmetric carbon atom and are thus prevented from racemization. The effect of the pure enantiomers of the thalidomide-analogues and also of the enantiomers of thalidomide on release of TNF-alpha was tested in vitro by using stimulated peripheral mononuclear blood cells. Both enantiomers of thalidomide inhibited the release of TNF-alpha equally well at low concentrations (5 and 12.5 micrograms/ml) but at higher concentrations (25 and 50 micrograms 50 micrograms/ml) there was a weak but statistically significant selectivity towards the (-)-(S)-enantiomer. In the case of the configuration-stable thalidomide-analogues there was a very pronounced and statistically significant enantioselectivity towards the (S)-form even at lower concentrations (> or = 5 micrograms/ml). The (S)-enantiomers of the thalidomide-analogues differed in their inhibitory potency from (-)-(S)-thalidomide suggesting that the introduction of the methyl-group increases the TNF-alpha-inhibitory activity while the reduction of one of the carbonyl-functions in the glutarimide-moiety to a methylene-group decreases activity. The effect of these small molecular alterations on activity and the enantioselectivity towards the (S)-enantiomers may indicate that thalidomide and its analogues directly interact with one or several cellular target-proteins.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0899-0042
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
8
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
390-6
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:8900028-Cells, Cultured,
pubmed-meshheading:8900028-Humans,
pubmed-meshheading:8900028-Immunosuppressive Agents,
pubmed-meshheading:8900028-Kinetics,
pubmed-meshheading:8900028-Molecular Conformation,
pubmed-meshheading:8900028-Stereoisomerism,
pubmed-meshheading:8900028-Structure-Activity Relationship,
pubmed-meshheading:8900028-Thalidomide,
pubmed-meshheading:8900028-Tumor Necrosis Factor-alpha
|
pubmed:year |
1996
|
pubmed:articleTitle |
Enantioselective inhibition of TNF-alpha release by thalidomide and thalidomide-analogues.
|
pubmed:affiliation |
Department of Molecular Pharmacology, Gruenenthal Centre of Research, Aachen, Germany.
|
pubmed:publicationType |
Journal Article
|